Induced GnasR201H expression from the endogenous Gnas locus causes fibrous dysplasia by up-regulating Wnt/β-catenin signaling

Sanjoy Kumar Khan, Prem Swaroop Yadav, Gene Elliott, Dorothy Zhang Hu, Ruoshi Xu, and Yingzi Yang
PNAS January 16, 2018 115 (3) E418-E427; first published November 20, 2017 https://doi.org/10.1073/pnas.1714313114

  1. Edited by John T. Potts, Massachusetts General Hospital, Charlestown, MA, and approved October 23, 2017 (received for review August 15, 2017)

See related content:

Significance

Understanding molecular and cellular mechanisms of rare genetic diseases provides invaluable insights into the human biology and pathology of both rare and related common diseases. Fibrous dysplasia (FD) is a mosaic disease resulting from postzygotic activating mutations of GNAS. The mouse models we created allowed us to precisely model FD by expressing the FD Gαs mutation under the control of its endogenous genetic locus. We found in our FD mouse models that up-regulated Wnt/β-catenin signaling resulted in impaired differentiation and proliferation of bone marrow stem cells, which in turn caused marrow fibrosis. Our work provides a solid new foundation for therapeutic development of FD and understanding the principles whereby Gαs signaling governs bone formation and maintenance and bone marrow stromal cell differentiation.

Abstract

Fibrous dysplasia (FD; Online Mendelian Inheritance in Man no. 174800) is a crippling skeletal disease caused by activating mutations of the GNAS gene, which encodes the stimulatory G protein Gαs. FD can lead to severe adverse conditions such as bone deformity, fracture, and severe pain, leading to functional impairment and wheelchair confinement. So far there is no cure, as the underlying molecular and cellular mechanisms remain largely unknown and the lack of appropriate animal models has severely hampered FD research. Here we have investigated the cellular and molecular mechanisms underlying FD and tested its potential treatment by establishing a mouse model in which the human FD mutation (R201H) has been conditionally knocked into the corresponding mouse Gnas locus. We found that the germ-line FD mutant was embryonic lethal, and Cre-induced Gnas FD mutant expression in early osteochondral progenitors, osteoblast cells, or bone marrow stromal cells (BMSCs) recapitulated FD features. In addition, mosaic expression of FD mutant Gαs in BMSCs induced bone marrow fibrosis both cell autonomously and non-cell autonomously. Furthermore, Wnt/β-catenin signaling was up-regulated in FD mutant mouse bone and BMSCs undergoing osteogenic differentiation, as we have found in FD human tissue previously. Reduction of Wnt/β-catenin signaling by removing one Lrp6 copy in an FD mutant line significantly rescued the phenotypes. We demonstrate that induced expression of the FD Gαs mutant from the mouse endogenous Gnas locus exhibits human FD phenotypes in vivo, and that inhibitors of Wnt/β-catenin signaling may be repurposed for treating FD and other bone diseases caused by Gαs activation.

Fibrous dysplasia (FD) of bone (Online Mendelian Inheritance in Man no. 174800) is a severe form of skeletal disorder resulting in deformity, fracture, and pain in the affected bone. FD is well-characterized by bone marrow fibrosis; the bone marrow space is devoid of both hematopoietic tissue and adipocytes and replaced with fibrotic tissue. FD bone also exhibits abnormal architecture (“Chinese writing” pattern), structure, and mineral content of bone trabeculae (1⇓–3). These complex changes result in a mechanically incompetent, brittle, and fracture-prone bone that can cause wheelchair confinement of severely affected individuals. FD is a rare skeletal genetic disorder caused by mosaic activating mutations (R201H or R201C) of the α-subunit of stimulatory G protein (Gαs) encoded by GNAS (4⇓–6). The activating mutant Gαs loses inherent GTPase activities and remains in a constitutively active form that stimulates excessive cAMP production (7). FD occurs in isolation or with other clinical features such as skin pigmentation and endocrine dysfunction in McCune–Albright syndrome (MAS) (8, 9). Lack of inheritance of FD/MAS (4, 5, 10, 11) is likely due to embryonic lethality caused by germ line-transmitted activating GNAS mutations, which can only survive through mosaicism (12).

There is no cure for FD, as the molecular and cellular mechanisms of this skeletal disease that can be devastating in some cases remain largely unknown. Mouse models are indispensable tools for elucidating the natural history of human diseases and designing and testing novel treatments. Better understanding of FD is essential to providing new insights into marrow fibrosis and the regulation of osteoblast differentiation and maturation from bone marrow stromal cells (BMSCs, also called bone marrow-derived stem cells), but the lack of appropriate animal models has severely hampered research advancement and therapeutic development for FD. The existing in vivo models are either based on xenotransplantation of GNAS-mutated human skeletal progenitor cells into immunocompromised mice (11) or transgenic mouse models in which either an engineered Gαs-coupled receptor or a mutated rat Gnas transgene was driven by artificial promoters (13⇓–15). As none of these models were able to accurately recapitulate pathophysiological characteristics of human FD, the development of a “knockin” (KI) mouse model in which the corresponding mouse mutant Gαs can be expressed from its endogenous locus is absolutely necessary.

Here we have successfully created a KI mouse line, Gnasf(R201H), in which the human FD mutation (R201H) has been conditionally “knocked into” the corresponding mouse Gnas locus to allow FD mutant Gnas expression from its endogenous genetic locus with temporal and tissue specificity upon Cre induction. Using this mouse line, we show that FD mutant Gnas expression in both osteochondral progenitor cells and osteoblast progenitor cells in the Prrx1 and Osx lineages, respectively, replicated human FD phenotypes. Furthermore, mosaic analysis showed that FD mutant Gnas expression in Sox9+ BMSCs exhibits both cell-autonomous and non–cell-autonomous activities in causing FD phenotypes. Molecularly, as we have found in human FD bone previously, the FD mutant Gαs up-regulated Wnt/β-catenin signaling in bone and BMSCs, reduction of which significantly rescued FD phenotypes in GnasR201H mice, providing important therapeutic insights.

Results

The GnasR201H Mutation Is Embryonic Lethal.

Previously established mouse models have contributed to our current understanding of FD (13⇓–15); however, due to the transgenic nature of the reported FD mouse lines and some inconsistent results obtained from these models, many outstanding questions remain unanswered. To further understand the critical roles of Gnas in multiple aspects of bone formation, maintenance, and resorption, including regulation of BMSCs as well as onset, progression, and cellular origins of FD, we have established a mouse line that allows conditional expression of mouse mutant Gαs containing a corresponding human FD mutation, R201H (4⇓–6), from the endogenous mouse Gnas locus. This conditional KI Gnas allele [hereafter denoted Gnasf(R201H)] was generated by homologous recombination in embryonic stem cells (Fig. S1A). The Gnas coding exon sequence is highly conserved between human and mouse (>90% sequence identity) both at nucleotide and amino acid levels (Fig. S2 A and B). The correctly targeted Gnasf(R201H) allele expressed mutant Gnas, which we denote as GnasR201H, only in the presence of Cre expression; otherwise, it expressed a wild-type Gnas containing the minigene cassette (Figs. S1A and S2C).

Mosaicism of the human FD GNAS R201H mutation suggested that GNASR201H germ-line transmission may cause embryonic lethality. The Gnasf(R201H) allele we generated allowed us to test this directly by expressing GnasR201H in the early epiblast [before embryonic day (E)6.5] using the Sox2-Cre line that expresses Cre in mouse oocytes (16). Indeed, all Gnasf(R201H)/+; Sox2-Cre mutants with GnasR201H heterozygous expression were found to be much smaller than wild-type littermate controls at E10.5 and dead some time between E12.5 and E15.5 (Fig. 1A). Expression of the mutant allele was confirmed by sequencing the Gnas cDNA made from whole embryos (Fig. S2C). Because Gαs signaling regulates both Wnt and Hedgehog (Hh) signaling (17, 18), we examined signaling activities of the Wnt and Hh pathways by whole-mount in situ hybridization as well as real-time quantitative PCR (qRT-PCR). Our results showed that while there was a significant up-regulation in the expression of Tcf1 and Axin2 (Fig. 1 B and C), which are Wnt/β-catenin target genes (19), expression of Gli1 and Ptch1 (Fig. 1 D and E), which are Hh signaling target genes (20⇓–22), was down-regulated. Shh expression itself was not altered in the mutant embryos (Fig. S2D). Therefore, GnasR201H expression in early embryos enhanced Wnt/β-catenin signaling, while it suppressed Hh signaling. The mutant embryos at E10.5 exhibited severe heart development retardation (Fig. S2E) as well as increased cell death and reduced cell proliferation in the entire embryo (Fig. S2 F and G). As Wnt/β-catenin and Hh signaling are two key signaling pathways required to regulate various aspects of early embryonic development (19, 23⇓⇓–26), it is likely that dysregulation of both by the activating R201H Gαs has caused embryonic lethality.

Fig. 1.
Fig. 1.

Germ-line expression of GnasR201H causes embryonic lethality. (A) Lateral view of E10.5 and E12.5 littermate embryos with the indicated genotypes. (B and D) Representative images of whole-mount in situ hybridization performed with E9.5 embryos. (C and E) qRT-PCR analysis of the indicated gene expression from RNA isolated from whole embryos at E9.5. *P < 0.05; data are presented as mean ± SD. (Scale bars, 100 mm.)

GnasR201H Expression in Osteochondral Progenitor Cells Exhibits FD Features.

As FD-causing GNAS mutations are thought to occur at an early embryonic stage, we hypothesized that GnasR201H expression in early mouse osteochondral progenitor cells should phenocopy human FD. To test our hypothesis, Gnasf(R201H) mice were crossed with the Prrx1-Cre line, in which Cre is expressed in early limb bud mesenchyme cells (27). All Prrx1-Cre; Gnasf(R201H)/+ pups were born alive at Mendelian ratio and were readily distinguishable from wild-type littermates at birth due to their shorter limbs. The Prrx1-Cre; Gnasf(R201H)/+ mice manifested marked shortening of the limbs with severe bone deformity (Fig. 2A) throughout their adulthood (Fig. S3 A, B, and D), while the Gnasf(R201H)/+ littermate controls were normal and used as wild-type control in all analyses. Despite the short and misshapen limbs, bones in the trunk were normal and the mutant mice survived for more than 7 months with no sign of other gross sickness (Fig. S3 C and D). In Prrx1-Cre; Gnasf(R201H)/+ mice, the bone marrow space was occupied by woven trabecular bone and there was no cortical bone (Fig. 2B and Fig. S3D). Histomorphometric analysis showed that the trabecular thickness and trabecular number were significantly increased, whereas trabecular spacing was decreased in mutant bone (Fig. S3 E and F).

Fig. 2.
Fig. 2.

Prrx1-Cre; Gnasf(R201H)/+ mutant mice exhibit FD phenotypes. (A and B) Representative µCT scans of forelimbs from P21 mice with the indicated genotypes. Long bones were deformed in the mutant. Longitudinal and cross-sectional images of the humerus (B) showed that bone marrow space was occupied by trabecular bone in mutant mice. (C) Representative H&E staining of the trabecular region of P21 mouse humerus. Boxed regions are enlarged (Bottom); b, bone; ft, fibrous tissues. (D) von Kossa staining showing mineralization in humerus sections of P21 littermate control and mutant mice. (E) Quantification of mineralization in humerus from P21 mice as the percent of osteoid surface (OS) of bone surface (BS) (n = 3). (F) Western blot analysis for β-catenin and Gαs from the cell lysates of P6 humerus. IB, immunoblotting. (G) Immunohistochemistry of β-catenin on humerus sections of P6 littermate control and mutant mice. **P < 0.001; data are presented as mean ± SD.

Histological analysis further revealed abnormal architecture, structure, and mineral content of long bones in the Prrx1-Cre; Gnasf(R201H)/+ mutant mice (Fig. 2 C and D). The growth plate cartilage was disorganized and expanded in the mutant compared with the control (Fig. S3G). The marrow cavity was much reduced and the marrow space was occupied by trabecular bone and fibrous tissue with an appearance of the characteristic Chinese writing pattern (Fig. 2C). Reduced mineralization in the mutant bones was shown by von Kossa staining, and the increased osteoid surface demonstrated poor mineralization of increased bone formation in the Prrx1-Cre; Gnasf(R201H)/+ mutant mice (Fig. 2 D and E). Increased β-catenin protein levels were found in mutant long bones of postnatal day (P)6 pups (Fig. 2 F and G), supporting our previous findings in human FD bone (17). While poorly mineralized bone formation was increased, differentiation of osteoclasts from the Prrx1-Cre− hematopoietic lineage shown by tartrate-resistant acid phosphatase (TRAP) staining on the bone surface of the mutant mice was also increased (Fig. S3 H and I). This is a characteristic feature of human FD (28). In addition, Rankl expression was increased in Prrx1-Cre; Gnasf(R201H)/+ mutant bone (Fig. S3J), suggesting that activating Gαs signaling in osteoblasts has up-regulated Rankl expression, as has been shown for osteoblast-derived parathyroid hormone-related peptide (PTHrP) that signals through Gαs and promotes Rankl expression directly (29, 30). All these phenotypes of Prrx1-Cre; Gnasf(R201H)/+ mutant mice closely resemble those found in human FD. Therefore, embryonic expression of the activating R201H mutant Gαs in limb bud osteochondral progenitor cells recapitulated human FD phenotypes in adult long bones. It is important to note again that GnasR201H heterozygous expression was sufficient to produce FD phenotypes in mice and that the phenotypes were the same in male or female mice regardless of whether GnasR201H is provided maternally or paternally, as is the case in human FD (31).

Progression of FD Phenotypes in Prrx1-Cre; Gnasf(R201H)/+ Mutant Mice.

In humans, FD lesions start in embryonic development, progress during childhood, and remain static or sometimes improve in later stages of life (32). However, detailed tissue analysis of disease progression was not possible in human patients. The conditional Prrx1-Cre; Gnasf(R201H)/+ mutant mice therefore allowed us to investigate the onset and progression of FD phenotypes to gain a better understanding of the natural history of FD disease.

Well-formed cortical bone, a marrow cavity with primary spongiosa next to the growth plate, and cartilaginous epiphyses can be seen in control mice starting from P0 (Fig. S4A), but the long bone of P0 Prrx1-Cre; Gnasf(R201H)/+ mice showed no indication of bone formation (Fig. S4A). By P6, Prrx1-Cre; Gnasf(R201H)/+ mice showed bone formation, but marrow space was occupied by osseous trabecular tissue and the growth plate was increased in length (Fig. S4B). At 3 wk of age, there was more bone formation in the Prrx1-Cre; Gnasf(R201H)/+ mice with the same abnormalities as observed at P6: an irregular and thickened growth plate, lack of cortical bone, and expanded woven trabecular bone (Fig. S4C). These phenotypes were also observed in 2- and 4-mo-old Prrx1-Cre; Gnasf(R201H)/+ mice (Figs. S3D and S4D). Bone marrow fibrosis was observed from P6 onward.

The phenotypes of increased growth plate and delayed bone formation resembled those observed in mice in which either PTHrP or a constitutively active PTH/PTHrP receptor found in Jansen’s metaphyseal chondrodysplasia (JMC) (33) was expressed in chondrocytes, which led to chondrodysplasia and delayed bone formation (34, 35). As the PTH/PTHrP receptor is coupled with Gαs (36), delayed bone formation and growth plate abnormalities in Prrx1-Cre; Gnasf(R201H)/+ mice indicated that PTH/PTHrP signaling has been enhanced in the limb. Chondrocyte hypertrophy in long bone development is tightly regulated by a negative feedback loop formed by Indian Hedgehog (Ihh) and PTHrP (37⇓–39), and enhanced PTHrP signaling delays chondrocyte hypertrophy (40, 41). To examine chondrocyte hypertrophy, we analyzed E15.5 and E18.5 embryonic cartilage in the limb both histologically and molecularly (Fig. S5). Marker expression of nonhypertrophic (Col2) (42, 43), prehypertrophic (Ihh) (38, 44), hypertrophic (Col10), and late hypertrophic chondrocytes (Mmp13) (45⇓–47) was examined (Fig. S5C). In the mutant section, Col2 expression was detected everywhere at the expense of Ihh, Col10, and Mmp13 expression. In addition, delay of chondrocyte hypertrophy and the resulting delayed Ihh expression (Fig. S5C) caused delay in osteoblast differentiation in the mutant, shown by delayed osteoblast marker Osterix (Osx) expression (Fig. S5D). Taken together, Gαs activation delayed chondrocyte hypertrophy, which in turn delayed bone formation in embryos. Abnormal woven bone formation started postnatally and progressed rapidly with marrow fibrosis in Prrx1-Cre; Gnasf(R201H)/+ mice. In addition, as a PTH/PTHrP receptor mutation was found in a few enchondroma patients and transgenic expression of one mutant PTH/PTHrP receptor led to enchondroma formation, supporting a role of the cAMP/PKA pathway in the development of enchondromas (48), some of the abnormal cartilage in older Prrx1-Cre; Gnasf(R201H)/+ mice resembled enchondroma-like lesions in some FD patients (49, 50) (Fig. S4D, arrows).

GnasR201H Expression Impairs Osteoblastic Differentiation of Bone Marrow Mesenchymal Stem Cells.

It has previously been shown that Gαs signaling plays a critical role in osteoblast differentiation from mesenchymal progenitor cells by modulating activities of the Wnt/β-catenin and Hh signaling pathways; both play fundamental roles in skeletal development, and defects in these signaling pathways cause skeletal diseases (18, 51, 52). In FD patients, there is extensive marrow fibrosis, and fibrotic cells in the marrow are arrested at early osteoblast differentiation stages (53, 54), suggesting that in adults, FD mutations cause aberrant osteoblast differentiation of BMSCs that contain stem cells. To test whether GnasR201H expression in mouse BMSCs affects their osteogenic potential, we isolated BMSCs from Gnasf(R201H)/+ mice and infected them with adenoviruses carrying Cre or GFP (Ad-Cre or Ad-GFP). Cre expression in BMSCs induced GnasR201H expression and thus activated PKA, shown by increased CREB phosphorylation (55, 56) (Fig. 3A). The GnasR201H-expressing BMSCs cultured in osteogenic medium showed marked reduction in alkaline phosphatase (ALP) activity and mineralization (Fig. 3B). In addition, expression of osteogenic genes, such as Osx and Osteocalcin (Ocn), were significantly down-regulated (Fig. 3C). Importantly, GnasR201H expression in BMSCs also reduced colony-forming units, suggesting that activated Gαs reduced stemness and/or proliferation of BMSCs (Fig. 3D). Furthermore, β-catenin protein levels were increased and expression of Wnt/β-catenin target genes Axin2 and Tcf1 were significantly up-regulated (Fig. 3 E and F) while Hh signaling was down-regulated in mutant BMSCs (Fig. 3G), consistent with our previous findings (17, 18, 51) that activated Gαs promotes Wnt/β-catenin signaling and inhibits Hh signaling.

Fig. 3.
Fig. 3.

GnasR201H expression impairs osteoblastic differentiation of BMSCs. (A) Western blot analysis of phosphorylated CREB and Gαs in cell lysates of BMSCs 7 d after being transduced with Ad-Cre and Ad-GFP. (B) ALP and alizarin red staining of BMSCs after osteogenic differentiation for 7 and 14 d, respectively. (C) qRT-PCR analysis of osteogenic marker expression from the RNA isolated from BMSCs 7 d post differentiation after being transduced with Ad-Cre or Ad-GFP. (D) Colony-forming assay of BMSCs transduced with Ad-Cre or Ad-GFP. (E) Western blot analysis of β-catenin in BMSCs 7 d after being transduced with Ad-Cre or Ad-GFP. (F and G) qRT-PCR analysis of signaling target genes of the Wnt (Axin2 and Lef1) and Hedgehog (Hip1 and Gli1) pathways from RNA isolated from BMSCs 7 d after being transduced with Ad-Cre and Ad-GFP. *P < 0.05, **P < 0.001; data are presented as mean ± SD.

Mosaic Analysis Reveals Non–Cell-Autonomous Roles of the Gαs FD Mutation in BMSCs.

As FD in humans is caused by somatic mosaicism of Gαs mutations, to model this disease more accurately, we created a mosaic state of the GnasR201H mutation in vivo in bone by crossing the Gnasf(R201H) line with Sox9-CreER; Rosa26Td-Tomato mice to generate Gnasf(R201H); Sox9-CreER; Rosa26Td-Tomato mice. The Sox9-CreER line was chosen, as it has been shown to be expressed in BMSCs after birth apart from its expression in chondrocytes (57). Tamoxifen (TM)-injected mosaic mutant mice exhibited increased bone volume as well as trabecular number and thickness and displayed an irregular growth plate architecture (Fig. S6 A and B) similar to, but less severe than, the phenotypes of Prrx1-Cre; Gnasf(R201H) mice. Tdtomato marked the GnasR201H mutant cells, and increased CREB phosphorylation was found in Tdtomato+ cells, confirming Gαs activation (Fig. S6C). Interestingly, Osx+ osteoprogenitor cells were increased in the Tdtomato+ population while Osteopontin (Opn+) cells were reduced (Fig. 4 A, A′, B, and B′), indicating that GnasR201H expression promotes osteoblast differentiation from BMSCs but inhibits osteoblast maturation in vivo. Consistent with findings in Prrx1-Cre; Gnasf(R201H) mice, β-catenin expression was increased in the Tdtomato+ population (Fig. S6E).

Fig. 4.
Fig. 4.

Mosaic expression of GnasR201H causes enhanced bone fibrosis but reduced bone maturation. Immunostaining (A–D and A′–D′) and quantification (A″–D″) of marker expression as indicated in TdTomato-labeled mutant [Sox9-CreER; Rosa26TdTomato; Gnasf(R201H)] in wild-type (Sox9-CreER; Rosa26TdTomato) cells. TM was injected at P5 and the humerus was sectioned at P21 for analysis. *P < 0.05, **P < 0.001; data are presented as mean ± SD. Opn+ and Osx+ cells refer to Opn+; TdTomato+ and Osx+; TdTomato+ double-positive cells.

The growth plate was very disorganized in the TM-injected Sox9-CreER; Rosa26Td-Tomato; Gnasf(R201H) mutant mice. As chondrocyte hypertrophy is synchronized in wild-type mice, we asked whether disorganization of the mutant growth plate was caused by asynchronous hypertrophy due to mosaic expression of GnasR201H. Indeed, Col10 immunostaining showed that the GnasR201H-expressing Tdtomato+ chondrocyte column was much increased in length compared with the wild-type Tdtomato+ chondrocyte column or Tdtomato− one (Fig. 4 C–C′′), demonstrating that GnasR201H expression significantly delayed chondrocyte hypertrophy cell autonomously.

As bone marrow fibrosis is a prominent feature of FD, we also found extensive fibrotic tissue in bone marrow of TM-injected Gnasf(R201H); Sox9-CreER; Rosa26Td-Tomato mutant mice compared with the TM-injected wild-type control (Fig. S6B). When analyzed with a fibrosis marker, αSMA (58), there was an increase of αSMA+ cells in the mutant mice (Fig. 4 D–D′′). This was further confirmed by much increased αSMA expression in GnasR201H-expressing BMSCs (Fig. S6D). Interestingly, many of the αSMA+ cells were Tdtomato−, suggesting that they were wild-type cells with no GnasR201H expression (Fig. 4D′). In addition, these αSMA+; Tdtomato− cells were not associated with CD31+ endothelial cells (Fig. S6 F and G), indicating they were not smooth muscle cells associated with blood vessels. Therefore, GnasR201H expression in BMSCs also caused FD, and mosaic analysis allowed uncovering non–cell-autonomous activities of GnasR201H in bone marrow fibrosis.

Wnt/β-Catenin Signaling Plays a Key Role in FD Pathogenesis.

As Prrx1-Cre and Sox9-CreER are also expressed in chondrocytes, to investigate whether GnasR201H expression in early osteoblast progenitors would lead to FD, we crossed the Gnasf(R201H) line with the Osx-GFP::Cre line, a tetracycline responsive element (tetO)-controlled GFP::Cre fusion gene expression driven by the Osx promoter (59). To our surprise, mutant mice died immediately after birth, possibly due to general bone defects throughout the body. To get around this, we suppressed GFP::Cre expression by feeding pregnant female mice with doxycycline in water starting at E11.5 until birth. The pups were born with grossly normal morphology but, at weaning, mutant mice showed strong FD phenotypes, though less severe than the Prrx1-Cre; Gnasf(R201H) mice (Fig. 5 A and B). As we found that Wnt/β-catenin signaling was highly up-regulated in both Prrx1-Cre– and Sox9-CreER–driven mutants, we decided to genetically down-regulate it in this less severe FD model to see if reducing Wnt/β-catenin signaling can rescue the FD phenotype by generating Osx-GFP::Cre; Gnasf(R201H); Lrp6c/+ mice. Lrp6 is a Wnt coreceptor that transmits canonical Wnt/β-catenin signaling (60). Interestingly, removing one Lrp6 copy in Osx-GFP::Cre; Gnasf(R201H) mutant mice resulted in significant rescue of FD phenotypes. Microcomputed tomography (μCT) as well as histological analysis showed obvious rescue of bone marrow space and cortical bone as well as reduction of bone marrow fibrosis (Fig. 5 A and B). Wnt/β-catenin target gene expression was reduced by Lrp6 removal (Fig. 5C). Furthermore, expression of early osteoblast differentiation markers such as Runx2 and Alp was reduced, while expression of mature osteoblast markers Ocn and Opn was increased and fibrosis marker Timp1 was decreased in the rescued mutants (Fig. 5C). Therefore, up-regulated canonical Wnt/β-catenin signaling plays a key role in mediating the effects of Gnasf(R201H) expression in FD. Osteoclast differentiation was not altered by removing Lrp6 (Fig. S7). To further test the therapeutic value of small-molecule inhibitors of Wnt/β-catenin signaling in improving bone mineralization inhibited by GnasR201H, we treated GnasR201H-expressing BMSCs at the beginning of osteogenic differentiation with LGK-974, a potent small-molecule inhibitor of Wnt secretion (61). LGK-974 treatment dose dependently improved mineralization in GnasR201H mutant BMSCs (Fig. 5 D and E), which was confirmed by reduced Wnt signaling and increased osteogenic marker expression (Fig. 5 F and G). Taken together, both in vivo and in vitro experiments demonstrate that up-regulated canonical Wnt/β-catenin signaling mediates the function of GnasR201H in causing FD, and that Wnt/β-catenin signaling may be a critical therapeutic target for treating FD.

Fig. 5.
Fig. 5.

Up-regulated Wnt/β-catenin signaling plays a key role in FD. (A) Representative µCT scans of the humerus of littermate control [Gnasf(R201H)/+] and OsxCre; Gnasf(R201H)/+ and OsxCre; Gnasf(R201H)/+; Lrp6C/+ mutant mice. Sagittal and transverse section views of humerus are also shown. (B) H&E staining of humerus sections from P21 mice of the indicated genotypes. (C) qRT-PCR analysis of humerus bones from mice with the indicated genotypes. (D) Alizarin red staining of BMSCs transduced with Ad-Cre and Ad-GFP viruses 7 d after osteogenic differentiation. At day 0 of osteogenic differentiation, BMSCs were treated with DMSO or LGK-974, a small molecule that inhibits Wnt secretion. (E) Alizarin red staining was quantified. (F and G) qRT-PCR analysis of gene expression in BMSCs at day 7 post differentiation. *P < 0.05, **P < 0.001; ns, not significant; data are presented as mean ± SD.

Discussion

Here we report the generation of a mouse model that allows the closest possible modeling of FD bone disease, a skeletal disorder originally described in 1942 (62). The conditional knockin approach allowed expression of GnasR201H corresponding to the human FD mutant from the Gnas locus with spatial and temporal control. This model can be used to study not only FD but also MAS, which has severe symptoms outside of the skeletal system. Germ-line expression of GnasR201H caused embryonic lethality, but Cre-induced GnasR201H expression in osteochondral progenitor cells, early osteoblast cells, or sporadically in postnatal BMSCs led to typical FD phenotypes. Embryonic lethality due to germ-line GnasR201H expression confirmed the longstanding hypothesis postulated by Happle that the disease genotype would be lethal if germ line‐transmitted, and is only able to survive through mosaicism (12). Successful development of the Gnasf(R201H) line has opened a door to elucidating many still poorly understood aspects of FD and MAS and to designing and testing novel FD treatment strategies.

Our finding, though consistent with the human FD etiology that is linked to missense activating GNAS mutations that occur after fertilization in somatic cells (5, 63), is in contrast with a previous finding in a transgenic model in which the human FD mutant transgene could survive through germ-line transmission (13). This is likely due to the transgenic nature of the previous model in which an artificial promoter was driving the mutant GNAS cDNA expression from a heterologous genomic locus, highlighting the necessity to express the FD mutant from the endogenous Gnas locus to precisely model the disease. Several other animal models have been generated in the past that contributed to our current understanding of FD. These models, though insightful in certain ways, are limited in others by their transgenic and interspecies tissue transplantation nature, which does not change the Gαs expressed from its endogenous locus as in FD human patients. Furthermore, these models could not be used to study other associated phenotypes found in MAS, where Gαs activation occurs outside of the skeleton.

Interestingly, we found that induced GnasR201H expression in osteochondral progenitor cells resulted in much delayed chondrocyte hypertrophy, a thickened growth plate, and a condition similar to enchondroma (Fig. S4D). It is well-recognized that an FD lesion may contain cartilage, though the amount is quite variable. Jaffe and Lichtenstein (64) in their original article on FD recognized that cartilage was “an integral part of the dysplastic process”; FD case reports have shown that multifocal FD has been found together with enchondroma-like areas in conditions of fibrocartilaginous dysplasia (FCD) (65, 66). The animal models we have generated provided invaluable insight and tools in understanding FD and FCD. The PTH/PTHrP receptor couples to Gαs and Gαq/11 (67⇓–69). Patients with JMC (characterized by short-limbed dwarfism, severe growth plate abnormalities, and hypercalcemia) and also a few patients with enchondroma alone (48) carry activating mutations in the PTH/PTHrP receptor that cause constitutive receptor activation (33, 70). Delayed chondrocyte hypertrophy and FCD-like lesions in our FD models resemble those caused by activated PTH/PTHrP receptor. It is interesting to observe that chondrocyte hypertrophy eventually occurred in Gnasf(R201H); Prrx1-Cre newborn pups (Fig. S4). As other signaling pathways can also regulate chondrocyte hypertrophy, it is possible that postnatally, the relative contribution of the PTH/PTHrP receptor in regulating chondrocyte hypertrophy is reduced.

The cellular origin of FD has remained largely unknown. Our data demonstrate that expression of FD mutation in early osteochondral progenitor cells or osteoblast lineage cells, or BMSCs, can establish similar human FD phenotypes. In all these FD models, consistent with our previous finding in human tissues (17), Wnt/β-catenin signaling was up-regulated; this is critical for FD phenotypes, as removal of one Lrp6 gene copy resulted in significant rescue of FD phenotypes, demonstrating that activated Wnt/β-catenin signaling is a key mechanism that induces FD. The function of Wnt signaling in bone formation has been shown to be dose- and stage-dependent. Sustained activation of Wnt/β-catenin signaling in mesenchymal progenitor cells and osteoblast lineages results in reduced mineralization and bone formation (ref. 17 and references therein). Both in vivo genetic rescue and in vitro chemical treatment showed that inhibition of Wnt/β-catenin signaling reduced FD phenotypes by promoting osteoblast maturation and reducing bone marrow fibrosis. Therefore, Wnt/β-catenin signaling inhibitors such as LGK-974 could be repurposed to treat FD, and our FD models are well-suited to test potential treatments for FD and McCune–Albright syndrome.

Materials and Methods

Mouse.

Animal care and experiments were performed in accordance with the Institutional Animal Care and Use Committee (IACUC) guidelines at the National Institutes of Health and the Harvard Medical School.

Immunohistochemistry and Western Blotting.

Immunohistochemistry was performed according to previously described methods (18). Western blotting was performed using standard techniques. Antibody information is provided in Supporting Information.

RNA in Situ Hybridization.

RNA in situ hybridization was performed using DIG-labeled antisense RNA probes as described before (71).

BMSC Isolation and Osteogenic Differentiation.

BMSCs were isolated by flushing the bone marrow cavity of 6-wk-old mice and plating cells in alpha-MEM, 20% FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin. Equal numbers of cells were then seeded in 12-well plates and infected with Ad-Cre or Ad-GFP before confluence. Cells were switched to osteogenic medium (17, 18) after confluence for the indicated time before analysis.

Adenovirus Cell Culture Treatment.

The Cre and GFP adenoviruses were made by SAIC-Frederick (∼1 × 1010 pfu/mL) and diluted 1:500 for infection.

Statistical Analysis.

Statistical significance was tested by two-tailed Student’s t test between two groups. P < 0.05 was considered significant. Data are presented as mean ± SD unless otherwise indicated.

Acknowledgments

We thank members of the Y.Y. laboratory for constructive discussions, and the Harvard School of Dental Medicine (HSDM) μCT core and Center for Skeletal Research at Massachusetts General Hospital for μCT scanning. This study was supported by NIH Grants R01DE025866 from National Institute of Dental and Craniofacial Research and R01AR070877 from National Institute of Arthritis and Musculoskeletal and Skin Diseases, the intramural research program of National Human Genome Research Institute, and the HSDM Dean’s Scholar fellowship (to S.K.K.).

Footnotes

  • ↵1To whom correspondence should be addressed. Email: yingzi_yang{at}hsdm.harvard.edu.

  • Author contributions: S.K.K. and Y.Y. designed research; S.K.K., P.S.Y., G.E., D.Z.H., and R.X. performed research; S.K.K., P.S.Y., and Y.Y. analyzed data; and S.K.K., P.S.Y., and Y.Y. wrote the paper.

  • The authors declare no conflict of interest.

  • This article is a PNAS Direct Submission.

  • This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1714313114/-/DCSupplemental.

Published under the PNAS license.

References

  1. ↵
    1. Riminucci M, et al.
    (1999) The histopathology of fibrous dysplasia of bone in patients with activating mutations of the Gs alpha gene: Site-specific patterns and recurrent histological hallmarks. J Pathol 187:249–258.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Riminucci M, et al.
    (1997) Fibrous dysplasia of bone in the McCune-Albright syndrome: Abnormalities in bone formation. Am J Pathol 151:1587–1600.
    OpenUrlPubMed
  3. ↵
    1. Robinson C,
    2. Collins MT,
    3. Boyce AM
    (2016) Fibrous dysplasia/McCune-Albright syndrome: Clinical and translational perspectives. Curr Osteoporos Rep 14:178–186.
    OpenUrl
  4. ↵
    1. Shenker A,
    2. Weinstein LS,
    3. Sweet DE,
    4. Spiegel AM
    (1994) An activating Gs alpha mutation is present in fibrous dysplasia of bone in the McCune-Albright syndrome. J Clin Endocrinol Metab 79:750–755.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Weinstein LS, et al.
    (1991) Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 325:1688–1695.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Schwindinger WF,
    2. Francomano CA,
    3. Levine MA
    (1992) Identification of a mutation in the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome. Proc Natl Acad Sci USA 89:5152–5156.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Lania A, et al.
    (1998) Constitutively active Gs alpha is associated with an increased phosphodiesterase activity in human growth hormone-secreting adenomas. J Clin Endocrinol Metab 83:1624–1628.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Adam MP, et al.
    1. Boyce AM,
    2. Collins MT
    (1993) Fibrous dysplasia/McCune-Albright syndrome. GeneReviews, ed Adam MP, et al. (Univ of Washington, Seattle).
  9. ↵
    1. Albright F,
    2. Butler AM,
    3. Hampton AO,
    4. Smith P
    (1937) Syndrome characterized by osteitis fibrosa disseminata, areas of pigmentation and endocrine dysfunction, with precocious puberty in females Report of 5 cases. N Engl J Med 216:727–746.
    OpenUrlCrossRef
  10. ↵
    1. Shenker A, et al.
    (1993) Severe endocrine and nonendocrine manifestations of the McCune-Albright syndrome associated with activating mutations of stimulatory G protein GS. J Pediatr 123:509–518.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Bianco P, et al.
    (1998) Reproduction of human fibrous dysplasia of bone in immunocompromised mice by transplanted mosaics of normal and Gsalpha-mutated skeletal progenitor cells. J Clin Invest 101:1737–1744.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Happle R
    (1986) The McCune-Albright syndrome: A lethal gene surviving by mosaicism. Clin Genet 29:321–324.
    OpenUrlPubMed
  13. ↵
    1. Saggio I, et al.
    (2014) Constitutive expression of Gsα(R201C) in mice produces a heritable, direct replica of human fibrous dysplasia bone pathology and demonstrates its natural history. J Bone Miner Res 29:2357–2368.
    OpenUrl
  14. ↵
    1. Remoli C, et al.
    (2015) Osteoblast-specific expression of the fibrous dysplasia (FD)-causing mutation Gsα(R201C) produces a high bone mass phenotype but does not reproduce FD in the mouse. J Bone Miner Res 30:1030–1043.
    OpenUrl
  15. ↵
    1. Hsiao EC, et al.
    (2008) Osteoblast expression of an engineered Gs-coupled receptor dramatically increases bone mass. Proc Natl Acad Sci USA 105:1209–1214.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Hayashi S,
    2. Lewis P,
    3. Pevny L,
    4. McMahon AP
    (2002) Efficient gene modulation in mouse epiblast using a Sox2Cre transgenic mouse strain. Mech Dev 119(Suppl 1):S97–S101.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Regard JB, et al.
    (2011) Wnt/β-catenin signaling is differentially regulated by Gα proteins and contributes to fibrous dysplasia. Proc Natl Acad Sci USA 108:20101–20106.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Regard JB, et al.
    (2013) Activation of Hedgehog signaling by loss of GNAS causes heterotopic ossification. Nat Med 19:1505–1512.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Clevers H
    (2006) Wnt/beta-catenin signaling in development and disease. Cell 127:469–480.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Huangfu D,
    2. Anderson KV
    (2006) Signaling from Smo to Ci/Gli: Conservation and divergence of Hedgehog pathways from Drosophila to vertebrates. Development 133:3–14.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Bai CB,
    2. Auerbach W,
    3. Lee JS,
    4. Stephen D,
    5. Joyner AL
    (2002) Gli2, but not Gli1, is required for initial Shh signaling and ectopic activation of the Shh pathway. Development 129:4753–4761.
    OpenUrlPubMed
  22. ↵
    1. Goodrich LV,
    2. Johnson RL,
    3. Milenkovic L,
    4. McMahon JA,
    5. Scott MP
    (1996) Conservation of the hedgehog/patched signaling pathway from flies to mice: Induction of a mouse patched gene by Hedgehog. Genes Dev 10:301–312.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. van Amerongen R,
    2. Nusse R
    (2009) Towards an integrated view of Wnt signaling in development. Development 136:3205–3214.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Yang Y
    (2012) Wnt signaling in development and disease. Cell Biosci 2:14.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Varjosalo M,
    2. Taipale J
    (2008) Hedgehog: Functions and mechanisms. Genes Dev 22:2454–2472.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Chiang C, et al.
    (1996) Cyclopia and defective axial patterning in mice lacking Sonic hedgehog gene function. Nature 383:407–413.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Logan M, et al.
    (2002) Expression of Cre recombinase in the developing mouse limb bud driven by a Prxl enhancer. Genesis 33:77–80.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Riminucci M, et al.
    (2003) Osteoclastogenesis in fibrous dysplasia of bone: In situ and in vitro analysis of IL-6 expression. Bone 33:434–442.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Martin TJ
    (2005) Osteoblast-derived PTHrP is a physiological regulator of bone formation. J Clin Invest 115:2322–2324.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Mak KK, et al.
    (2008) Hedgehog signaling in mature osteoblasts regulates bone formation and resorption by controlling PTHrP and RANKL expression. Dev Cell 14:674–688.
    OpenUrlCrossRefPubMed
  31. ↵
    1. DiCaprio MR,
    2. Enneking WF
    (2005) Fibrous dysplasia. Pathophysiology, evaluation, and treatment. J Bone Joint Surg Am 87:1848–1864.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Hart ES, et al.
    (2007) Onset, progression, and plateau of skeletal lesions in fibrous dysplasia and the relationship to functional outcome. J Bone Miner Res 22:1468–1474.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Schipani E,
    2. Kruse K,
    3. Jüppner H
    (1995) A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia. Science 268:98–100.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. Weir EC, et al.
    (1996) Targeted overexpression of parathyroid hormone-related peptide in chondrocytes causes chondrodysplasia and delayed endochondral bone formation. Proc Natl Acad Sci USA 93:10240–10245.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Schipani E, et al.
    (1997) Targeted expression of constitutively active receptors for parathyroid hormone and parathyroid hormone-related peptide delays endochondral bone formation and rescues mice that lack parathyroid hormone-related peptide. Proc Natl Acad Sci USA 94:13689–13694.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. Jüppner H, et al.
    (1991) A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science 254:1024–1026.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    1. Karp SJ, et al.
    (2000) Indian hedgehog coordinates endochondral bone growth and morphogenesis via parathyroid hormone related-protein-dependent and -independent pathways. Development 127:543–548.
    OpenUrlAbstract
  38. ↵
    1. Vortkamp A, et al.
    (1996) Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein. Science 273:613–622.
    OpenUrlAbstract
  39. ↵
    1. Chung UI,
    2. Schipani E,
    3. McMahon AP,
    4. Kronenberg HM
    (2001) Indian hedgehog couples chondrogenesis to osteogenesis in endochondral bone development. J Clin Invest 107:295–304.
    OpenUrlCrossRefPubMed
  40. ↵
    1. Chung UI,
    2. Lanske B,
    3. Lee K,
    4. Li E,
    5. Kronenberg H
    (1998) The parathyroid hormone/parathyroid hormone-related peptide receptor coordinates endochondral bone development by directly controlling chondrocyte differentiation. Proc Natl Acad Sci USA 95:13030–13035.
    OpenUrlAbstract/FREE Full Text
  41. ↵
    1. Lanske B, et al.
    (1996) PTH/PTHrP receptor in early development and Indian hedgehog-regulated bone growth. Science 273:663–666.
    OpenUrlAbstract
  42. ↵
    1. Ng LJ,
    2. Tam PP,
    3. Cheah KS
    (1993) Preferential expression of alternatively spliced mRNAs encoding type II procollagen with a cysteine-rich amino-propeptide in differentiating cartilage and nonchondrogenic tissues during early mouse development. Dev Biol 159:403–417.
    OpenUrlCrossRefPubMed
  43. ↵
    1. Sandell LJ,
    2. Morris N,
    3. Robbins JR,
    4. Goldring MB
    (1991) Alternatively spliced type II procollagen mRNAs define distinct populations of cells during vertebral development: Differential expression of the amino-propeptide. J Cell Biol 114:1307–1319.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    1. Kronenberg HM
    (2003) Developmental regulation of the growth plate. Nature 423:332–336.
    OpenUrlCrossRefPubMed
  45. ↵
    1. Mattot V, et al.
    (1995) Expression of interstitial collagenase is restricted to skeletal tissue during mouse embryogenesis. J Cell Sci 108:529–535.
    OpenUrlAbstract/FREE Full Text
  46. ↵
    1. Yoshida CA, et al.
    (2004) Runx2 and Runx3 are essential for chondrocyte maturation, and Runx2 regulates limb growth through induction of Indian hedgehog. Genes Dev 18:952–963.
    OpenUrlAbstract/FREE Full Text
  47. ↵
    1. Linsenmayer TF, et al.
    (1991) Collagen types IX and X in the developing chick tibiotarsus: Analyses of mRNAs and proteins. Development 111:191–196.
    OpenUrlAbstract
  48. ↵
    1. Hopyan S, et al.
    (2002) A mutant PTH/PTHrP type I receptor in enchondromatosis. Nat Genet 30:306–310.
    OpenUrlCrossRefPubMed
  49. ↵
    1. Kalifa G,
    2. Adamsbaum C,
    3. Job-Deslande C,
    4. Dubousset J
    (1993) Fibrodysplasia ossificans progressiva and synovial chondromatosis. Pediatr Radiol 23:91–93.
    OpenUrlCrossRefPubMed
  50. ↵
    1. Clauser L,
    2. Marchetti C,
    3. Piccione M,
    4. Bertoni F
    (1996) Craniofacial fibrous dysplasia and Ollier’s disease: Combined transfrontal and transfacial resection using the nasal-cheek flap. J Craniofac Surg 7:140–144.
    OpenUrlPubMed
  51. ↵
    1. Day TF,
    2. Guo X,
    3. Garrett-Beal L,
    4. Yang Y
    (2005) Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell 8:739–750.
    OpenUrlCrossRefPubMed
  52. ↵
    1. Regard JB,
    2. Zhong Z,
    3. Williams BO,
    4. Yang Y
    (2012) Wnt signaling in bone development and disease: Making stronger bone with Wnts. Cold Spring Harb Perspect Biol 4:a007997.
    OpenUrlAbstract/FREE Full Text
  53. ↵
    1. Marie PJ,
    2. de Pollak C,
    3. Chanson P,
    4. Lomri A
    (1997) Increased proliferation of osteoblastic cells expressing the activating Gs alpha mutation in monostotic and polyostotic fibrous dysplasia. Am J Pathol 150:1059–1069.
    OpenUrlPubMed
  54. ↵
    1. Riminucci M,
    2. Robey PG,
    3. Saggio I,
    4. Bianco P
    (2010) Skeletal progenitors and the GNAS gene: Fibrous dysplasia of bone read through stem cells. J Mol Endocrinol 45:355–364.
    OpenUrlAbstract/FREE Full Text
  55. ↵
    1. Yamamoto KK,
    2. Gonzalez GA,
    3. Biggs WH III,
    4. Montminy MR
    (1988) Phosphorylation-induced binding and transcriptional efficacy of nuclear factor CREB. Nature 334:494–498.
    OpenUrlCrossRefPubMed
  56. ↵
    1. Bullock BP,
    2. Habener JF
    (1998) Phosphorylation of the cAMP response element binding protein CREB by cAMP-dependent protein kinase A and glycogen synthase kinase-3 alters DNA-binding affinity, conformation, and increases net charge. Biochemistry 37:3795–3809.
    OpenUrlCrossRefPubMed
  57. ↵
    1. Ono N,
    2. Ono W,
    3. Nagasawa T,
    4. Kronenberg HM
    (2014) A subset of chondrogenic cells provides early mesenchymal progenitors in growing bones. Nat Cell Biol 16:1157–1167.
    OpenUrlCrossRefPubMed
  58. ↵
    1. Meng F, et al.
    (2012) Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology 143:765–776.e3.
    OpenUrlCrossRefPubMed
  59. ↵
    1. Rodda SJ,
    2. McMahon AP
    (2006) Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development 133:3231–3244.
    OpenUrlAbstract/FREE Full Text
  60. ↵
    1. Pinson KI,
    2. Brennan J,
    3. Monkley S,
    4. Avery BJ,
    5. Skarnes WC
    (2000) An LDL-receptor-related protein mediates Wnt signalling in mice. Nature 407:535–538.
    OpenUrlCrossRefPubMed
  61. ↵
    1. Tammela T, et al.
    (2017) A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma. Nature 545:355–359.
    OpenUrlCrossRefPubMed
  62. ↵
    1. Lichtenstein LJ
    (1942) Fibrous dysplasia of bone. Arch Pathol (Chic) 33:777–816.
    OpenUrl
  63. ↵
    1. Weinstein LS,
    2. Chen M,
    3. Liu J
    (2002) Gs(alpha) mutations and imprinting defects in human disease. Ann N Y Acad Sci 968:173–197.
    OpenUrlCrossRefPubMed
  64. ↵
    1. Jaffe HL,
    2. Lichtenstein L
    (1942) Benign chondroblastoma of bone: A reinterpretation of the so-called calcifying or chondromatous giant cell tumor. Am J Pathol 18:969–991.
    OpenUrlPubMed
  65. ↵
    1. Vargas-Gonzalez R,
    2. Sanchez-Sosa S
    (2006) Fibrocartilaginous dysplasia (fibrous dysplasia with extensive cartilaginous differentiation). Pathol Oncol Res 12:111–114.
    OpenUrlCrossRefPubMed
  66. ↵
    1. Monappa V,
    2. Kudva R
    (2007) Multifocal fibrous dysplasia with enchondroma-like areas: Fibrocartilaginous dysplasia. Internet J Pathol 7:1–6.
    OpenUrl
  67. ↵
    1. Gardella TJ,
    2. Jüppner H
    (2001) Molecular properties of the PTH/PTHrP receptor. Trends Endocrinol Metab 12:210–217.
    OpenUrlCrossRefPubMed
  68. ↵
    1. Bringhurst FR, et al.
    (1993) Cloned, stably expressed parathyroid hormone (PTH)/PTH-related peptide receptors activate multiple messenger signals and biological responses in LLC-PK1 kidney cells. Endocrinology 132:2090–2098.
    OpenUrlCrossRefPubMed
  69. ↵
    1. Iida-Klein A, et al.
    (1997) Mutations in the second cytoplasmic loop of the rat parathyroid hormone (PTH)/PTH-related protein receptor result in selective loss of PTH-stimulated phospholipase C activity. J Biol Chem 272:6882–6889.
    OpenUrlAbstract/FREE Full Text
  70. ↵
    1. Schipani E, et al.
    (1999) A novel parathyroid hormone (PTH)/PTH-related peptide receptor mutation in Jansen’s metaphyseal chondrodysplasia. J Clin Endocrinol Metab 84:3052–3057.
    OpenUrlCrossRefPubMed
  71. ↵
    1. Prashar P,
    2. Yadav PS,
    3. Samarjeet F,
    4. Bandyopadhyay A
    (2014) Microarray meta-analysis identifies evolutionarily conserved BMP signaling targets in developing long bones. Dev Biol 389:192–207.
    OpenUrlCrossRef
View Abstract
Back to top
Article Alerts
Email Article
Citation Tools
Request Permissions
Endogenous GnasR201H expression causes FD in mice
Sanjoy Kumar Khan, Prem Swaroop Yadav, Gene Elliott, Dorothy Zhang Hu, Ruoshi Xu, Yingzi Yang
Proceedings of the National Academy of Sciences Jan 2018, 115 (3) E418-E427; DOI: 10.1073/pnas.1714313114
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Proceedings of the National Academy of Sciences: 116 (33)
Current Issue

Submit

Article Classifications

Jump to section

You May Also be Interested in

The ammonite in Burmese amber. Image courtesy of Bo Wang.
Rare instance of ammonite preserved in amber
Researchers report a marine ammonite from the Cretaceous Period preserved in Burmese amber from Myanmar, and the rare specimen in amber warrants exploration of the possibly exceptional circumstances of its fossilization.
Image courtesy of Bo Wang.
Virus. Image courtesy of Pixabay/qimono.
How dry air increases susceptibility to influenza
Exposure to low humidity makes mice infected with influenza more susceptible to severe disease by impairing airway tissue repair and innate antiviral defense, suggesting that controlling humidity may help curb influenza during winter.
Image courtesy of Pixabay/qimono.
mGluR5 availability linked to suicidal ideation (SI) in PTSD. Image courtesy of Margaret T. Davis and Irina Esterlis.
Potential biomarker for suicidal thoughts in PTSD
A study suggests a potential biomarker, the metabotropic glutamatergic receptor 5, for intervention and suicide risk management in posttraumatic stress disorder (PTSD).
Image courtesy of Margaret T. Davis and Irina Esterlis.

Similar Articles